CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
SENTI-202, a CAR NK cell therapy, achieved complete remission in several relapsed/refractory AML patients, showing potential as an effective treatment option. The off-the-shelf nature of SENTI-202 ...
The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies. The meeting continues as the longest‑running and only dedicated ...
Two patients with Waldenstrom’s NHL achieved complete remission with CAR NK cell therapy and rituximab, maintaining remission for 7 and 15 months without further treatment. The therapy is chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results